Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment (Johnston, et al, 2023)

Escrito por Michael DeMarco
Michael DeMarco

Psychedelic therapist, clinical sexologist, and Founding Fellow of Psychedelic Institute of Mental Health and Family Therapy / Consultor en Medicina Psicodélica, sexólogo clínico y miembro fundador del Instituto Psicodélico SAS

https://psychedelicmentalhealth.net/michael-demarco-therapist
Anterior

A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties (Sumner, et al, 2021)
Siguiente

Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches (Batievsky, et al, 2023)